ACTU (Actuate Therapeutics) Accounts Payable & Accrued Expense : $6.64 Mil (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Actuate Therapeutics Accounts Payable & Accrued Expense?

Actuate Therapeutics's quarterly accounts payable & accrued expense increased from . 20 ($0.00 Mil) to Dec. 2022 ($4.21 Mil) and increased from Dec. 2022 ($4.21 Mil) to Dec. 2023 ($6.64 Mil).

Actuate Therapeutics's annual accounts payable & accrued expense increased from . 20 ($0.00 Mil) to Dec. 2022 ($4.21 Mil) and increased from Dec. 2022 ($4.21 Mil) to Dec. 2023 ($6.64 Mil).

Actuate Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Actuate Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actuate Therapeutics Accounts Payable & Accrued Expense Chart

Actuate Therapeutics Annual Data

Trend

Dec22

Dec23

Accounts Payable & Accrued Expense

4.21

6.64

Actuate Therapeutics Semi-Annual Data
	Dec22	Dec23
Accounts Payable & Accrued Expense	4.21	6.64

Actuate Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Actuate Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actuate Therapeutics Inc (NAS:ACTU) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1751 River Run, Suite 400, Fort Worth, TX, USA, 76107

Website

https://www.actuatetherapeutics.com

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3?, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.